Pin Pharma, Inc.
Records under this name other than patents Pin Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Pin Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,878,001 | Immunosuppressive Tat derivative polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,927,580 | Tat-based immunomodulatory compositions and methods of their discovery and use Term ended Term ended Jul 7, 2026 · From the USPTO record | Term ended | Term ended Jul 7, 2026 | From the USPTO record |
| US 9,663,556 | Treatment of cancers with immunostimulatory HIV tat derivative polypeptides Lapsed on the fee record Ended May 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2025 | From the USPTO record |
| US 9,206,239 | Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides Lapsed on the fee record Ended Dec 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 8, 2023 | From the USPTO record |
| US 10,159,707 | Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides Lapsed on the fee record Ended Dec 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 25, 2022 | From the USPTO record |
| US 8,530,431 | Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides Lapsed on the fee record Ended Sep 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 10, 2021 | From the USPTO record |
| US 6,667,151 | Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease Term ended Term ended Aug 10, 2020 · From the USPTO record | Term ended | Term ended Aug 10, 2020 | From the USPTO record |
| US 8,323,928 | Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease Term ended Term ended Aug 10, 2020 · From the USPTO record | Term ended | Term ended Aug 10, 2020 | From the USPTO record |